Sepracor to acquire Oryx Pharma
Under the terms of the agreement, Oryx’s shareholders will receive $50 million and may become entitled to receive subsequent payments up to $20 million upon accomplishment of various
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.